May 5, 2017 / 12:21 PM / 3 months ago

BRIEF-Seattle Genetics terminates license agreement with Immunomedics

1 Min Read

May 5 (Reuters) - Seattle Genetics Inc:

* Seattle Genetics terminates license agreement with Immunomedics for sacituzumab govitecan (immu-132)

* As part of termination, Seattle Genetics will continue to hold 3.0 million shares of Immunomedics common stock

* Seattle Genetics-effective upon termination of license, parties agreed to fully settle, resolve, release each other from all disputes, claims, liabilities Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below